Beam Therapeutics, Inc. (BEAM) Stock Price, Financials & Summary

Price chart

Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21

Key dataOct 21, 2026

Open$24.83

From 52W high−34.49%

Volume1.17M

Market cap$2.57B

P/E (TTM)—

P/S (TTM)16.4x

Div yield—

Key dataOct 21, 2026

Open

$24.83

From 52W high

−34.49%

Volume

1.17M

Market cap

$2.57B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−26.3x

P/E (TTM)

—

RSI (14)

49.2

MomentumView details →

1D Return

−0.36%

YTD Return

−10.25%

SummaryUpdated Jun 1, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company founded in 2017 and based in Cambridge, Massachusetts. The company went public in February 2020 and has emerged as a leader in precision genetic medicine, specifically focusing on base editing technology to develop treatments for serious genetic diseases. Beam has built a comprehensive pipeline of experimental therapies targeting blood disorders, liver diseases, and other genetic conditions, with several programs advancing through clinical trials.

Ask drillr about Beam Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−26.3x

EV/Sales

10.6x

P/S (TTM)

16.4x

P/B (TTM)

2.4x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−54.75%

EBITDA Margin

−40.49%

ROE (TTM)

−8.00%

ROA (TTM)

−6.16%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

+158.88%

EPS YoY

+81.78%

FCF YoY

−4.84%

Revenue CAGR 3Y

+31.88%

EPS CAGR 3Y

+82.31%

EBITDA YoY

+84.05%

MomentumView details →

1D Return

−0.36%

YTD Return

−10.25%

1Y Return

−10.12%

RSI (14)

49.2

vs 50D SMA

−4.71%

vs 200D SMA

−12.12%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

14.57x

Quick Ratio

14.57x

Div Yield

—

Div Rate

—

Div Growth 1Y

−75.00%

EarningsView details →

EPS (Actual)

−$1.18

EPS Surprise

−6.31%

Beats (12Q)

4/12

Next Q EPS Est

−$1.18

Avg Surprise (4Q)

17.00%

Rev Surprise

−97.01%

Financials snapshotView financials →

Revenue (TTM)

156.03M

Net Income (TTM)

−85.43M

Op. CF (TTM)

−359.38M

Next earningsNov 3, 2026 →

Latest newsMore news →

Beam Therapeutics filed a lawsuit accusing former scientist Zi Jun "Emma" Wang of stealing intellectual property to co-found Shanghai-based YolTech Therapeutics, with YolTech and Serapha Bio named as defendants.23d ago

Similar companies

NewAmsterdam Pharma Company N.V.NAMS Laekna, Inc.02105.HK MBX Biosciences, Inc. Common StockMBX Viridian Therapeutics, Inc.VRDN ADMA Biologics, Inc.ADMA SELLAS Life Sciences Group, Inc.SLS Find similar companies →

Latest newsMore news →

Beam Therapeutics Inc. reported initial Phase 1/2 data for BEAM-301 showing restoration of endogenous glucose production after a single treatment and dose-dependent improvements in key GSDIa endpoints.9d ago Beam Therapeutics filed a lawsuit accusing former scientist Zi Jun "Emma" Wang of stealing intellectual property to co-found Shanghai-based YolTech Therapeutics, with YolTech and Serapha Bio named as defendants.23d ago